This message was sent to ##Email##
|
|
|
|
|
| |
AST
In preparation for the American Society of Transplantation Hepatitis C Consensus Conference on Jan 30-31, 2017, we would like to obtain some information on the current practices regarding the use of hepatitis C infected donor organs. Please take 15 minutes to complete this survey at your earliest convenience.
Your feedback is important, as it will help us better understand current practices regarding the use of hepatitis C positive donor organs. Thank you in advance for sharing your thoughts, as they will be valuable in framing what is currently happening in the transplant community as we open this meeting.
AST
In case you missed it, Dr. Chandraker had big news to share in this month's President's blog.
AST
In memory of former AST President and TIRN co-founder Daniel R. Salomon, the AST is partnering with the Salomon family to create a memorial fund entitled the Frontiers in Transplantation Endowment (FITE), designed to promote transformative science.
Learn more about FITE and how you can contribute.
AST
In November, the White House Office of Science & Technology Policy made a national call for commitments aimed at 1) breakthroughs in R&D, 2) closing the gap between supporters of organ donation and registered donors, and 3) increasing transplants and improving outcomes.
Last week, the White House released a blog that highlighted a number of new commitments. The AST was pleased to have a major new initiative included in the White House blog, announcing a new partnership with the Organ Preservation Alliance to create an AST Community of Practice focused on organ and tissue preservation. This community will provide resources and recruit researchers from a wide variety of disciplines to focus on preservation challenges, accelerating progress surrounding one of the key scientific opportunities to advance transplantation.
Read AST's press release to learn more about the COP and also AST's transformative approach to engage patients in the coming year.
 |
|
We are collaborating with the transplant community to improve the health of transplant patients through
• Innovative approaches and partnerships in data generation
• Working to improve long-term graft and patient survival
• Encouraging success through patient programs and outreach
We are committed to you, your patients, and the future of transplantation
|
|
ASN
The Department of Veterans Affairs and the American Society of Nephrology cordially invite you to submit a letter of interest to attend the Kidney Innovation Summit to be held February 9-10, 2017 in Washington, DC. With more than 20 million Americans affected by kidney disease and more than 650,000 reliant on dialysis or a transplant to stay alive, the approach to kidney disease requires transformation. As the 9th leading cause of death every year, kidney disease kills more people than breast or prostate cancer: the need for innovation is imperative.
Click here if you are interested in learning more about the meeting and how to submit a letter of interest.
University of Pittsburgh
The Thomas E. Starzl Transplantation Institute is accepting nominations for the 2018 Thomas E. Starzl Prize in Surgery and Immunology, awarded annually to a national or international leader in the field of organ transplantation and immunology.
READ MORE
AST
Get to know your colleague and visit the AST Member Spotlight page to find out what transplantation means to Dr. Peter Heeger and why he chose to work in this exciting field! Interested in being featured in the AST Member Spotlight? Please contact rpaulin@myAST.org for more information.
AST
Check out AST's archived webinars and journal clubs, and watch educational content when it's convenient for you. The AST also offers a variety of resources for different transplant specialties, all available on our easy-to-search website.
AST
January 18, 2016 1 p.m. Online Activity
For more information: https://www.myast.org/education/webinars/optimizing-your-living-kidney-donor-program
AST
The 2017 Cutting Edge of Transplantation (CEOT) meeting, scheduled for February 23-25, is an intimate scientific meeting for discussion and debate about how to improve the longevity of transplanted organs.
Experts that you recognize, as well as some that may be new to you from other fields, will address the topics that are most prevalent in the industry.
Highlighted this month is CEOT speaker Dr. Philip O’Connell PhD, FRACP, the Immediate Past President of The Transplantation Society and past President of the Transplantation Society of Australia and New Zealand. He is a Clinical Professor in Medicine at the University of Sydney and Director of Transplantation at Westmead Hospital and is the founding Director of the Centre for Transplant and Renal Research, The Westmead Institute for Medical Research. Dr. O’Connell’s presentation, Can We Predict the Future and Change it: Gocar, is scheduled for the first day of the conference.
Also speaking at CEOT in February is Dr. John Sedor, who graduated from the University of Virginia School of Medicine and trained in Medicine and Nephrology at University Hospitals of Cleveland/CWRU. His post-doctoral research was focused on mesangial cell signaling. He remained on the CWRU faculty, where he is the MetroHealth Research Endowment Professor of Medicine and Physiology and Biophysics. He has been a four-time Department of Medicine Teaching award winner and the recipient of the Chairman’s award in 2014. Dr. Sedor has lectured widely and is a member of both the Association of American Physicians and the American Clinical and Climatological Association.
Read more about Dr. O’Connell and Dr. Sedor and other CEOT speakers here.
See the program here, checking back often for the latest news and updates! Are you registered? Don’t hesitate - reserve your space now!
ATC
Registration for the 2017 American Transplant Congress in Chicago is now available!
Register by March 29, 2017 to take advantage of our early registration rates and guarantee your spot at our ticketed events.
Click here for more information regarding registration.
ATC
Abstracts submitted for late breaking consideration that do not include research conducted after Dec. 2, 2016, will not be considered for presentation.
The deadline to submit abstracts is Jan. 20, 2017, 11:59 p.m., PST.
For more information regarding abstract submission, please click here.
American Journal of Transplantation
Due to the enduring organ shortage, living donor liver transplantation has been a valuable treatment strategy for advanced liver disease patients for over 20 years. A variety of reviews have summarized the extensive data now available on medical and psychosocial risks to living donors in the aftermath of donation. However, evidence on donor medical and psychosocial outcomes beyond the first year postdonation has not been synthesized in any previous review.
READ MORE
American Journal of Transplantation
Organ shortage is the major limitation to kidney transplantation in the developed world. Conversely, millions of patients in the developing world with end-stage renal disease die because they cannot afford renal replacement therapy—even when willing living kidney donors exist. This juxtaposition between countries with funds but no available kidneys and those with available kidneys but no funds prompts us to propose an exchange program using each nation's unique assets.
READ MORE
Pediatric Nephrology
We have reviewed current evidence on the therapeutic drug monitoring (TDM) of mycophenolic acid (MPA) in relationship to drug efficacy and safety. The relationship between actual MPA exposure and mycophenolate mofetil (MMF) dose has been shown to be weak in children and adolescents. The TDM of MPA exposure should ideally be performed using full pharmacokinetic profiles or limited sampling strategies.
READ MORE
Contemporary Clinical Trials
Living donor kidney transplantation (LDKT) is the optimal treatment for end-stage kidney disease (ESKD). The evaluation process for a kidney transplant is complex, time consuming, and burdensome to the ESKD patient. Also, race disparities exist in rates of transplant evaluation completion, transplantation, and LDKT.
READ MORE
Heart Lung and Circulation
Heart transplantation allocation is often restricted from patients with low socioeconomic status (SES) due to concern for worse outcomes. We hypothesised that comorbidities would have a greater impact on risk of severe rejection post-orthotopic heart transplant than would Medicaid insurance and Median Household Income (MHI).
READ MORE
|
|
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063
|
